We take no money from the companies we review: no ads, no affiliate links, no sponsorships. Our editorial independence

HomeTrials › NCT07035093

Obesity & weight · Phase 3 · Active, not recruiting

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

NCT07035093 · Sponsor: Eli Lilly and Company

What this trial means for you

This study is active, not recruiting. It is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Retatrutide, Placebo for obesity, overweight, chronic low back pain (clbp).

Who can joinAll sexes, 18 Years and older
Healthy volunteersNo, diagnosis required
What you'd takeRetatrutide, Placebo
Study length~2.3 years overall
Planned participants586
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Have a history of axial-predominant low back pain * Have pain that is restricted to the low back or with a referral pattern limited to the proximal legs * Have a body mass index (BMI) ≥27 kilograms per square meter (kg/m2) at screening * Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * Have a non-axial origin low back pain * Have had botulinum or steroid injections to the spine within 1 year of screening * Have had trigger point injection to the spine within 6 months of screening * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days prior to screening * Have been taking drugs to promote body weight reduction, including over-the-counter medications, within 90 days prior to screening * Have a prior or planned surgical treatment for obesity * Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes

Study sites by state

Arizona

  • MD First Research - Chandler, Chandler
  • Tucson Orthopaedic Institute - North Wyatt Drive, Tucson

California

  • Ark Clinical Research - Fountain Valley, Fountain Valley
  • St Joseph Heritage Healthcare, Fullerton
  • Clinical Research Institute, Los Angeles
  • Artemis Institute for Clinical Research, San Diego

Colorado

  • Alpine Clinical Research Center, Boulder

Florida

  • K2 Medical Research - Daytona Beach, Daytona Beach
  • Flourish Research - Miami, LLC, Miami
  • IMA Clinical Research St. Petersburg, St. Petersburg
  • Care Access - Tampa, Tampa
  • Charter Research - Lady Lake, The Villages
  • Conquest Research, Winter Park

Kansas

  • Cotton O'Neil Clinical Research Center, Topeka

Louisiana

  • Care Access - Lake Charles (Bayou Pines), Lake Charles

Massachusetts

  • MedVadis Research Corporation, Waltham

Michigan

  • Great Lakes Research Group, Inc., Bay City

Missouri

  • Clinvest Headlands Llc, Springfield

North Carolina

  • Center for Clinical Research, Winston-Salem

Pennsylvania

  • Altoona Center For Clinical Research, Duncansville

Tennessee

  • New Phase Research and Development, Knoxville

Texas

  • FutureSearch Trials of Neurology, Austin
  • Mercy Family Clinic, Dallas
  • Houston Research Institute, Houston

Virginia

  • Sovah Clinical Research-River District, Danville

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently, so always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Keep researching on StudyBackedHealth